Forecasting the Demand for Companion Diagnostics (CDx) for CLDN18.2...

Forecasting the Demand for Companion Diagnostics (CDx) for CLDN18.2 and HER2: Evaluating 2026 Gains in Targeted Therapy Selection (2025–2032)

Posted 2026-04-01 07:05:11

108

The global healthcare community is placing an unprecedented emphasis on early intervention for gastrointestinal malignancies. The Gastric Cancer Diagnostics Market is at a pivotal juncture, transitioning from traditional symptomatic testing to advanced, biomarker-driven screening protocols. As gastric cancer remains one of the leading causes of cancer-related mortality worldwide, the demand for high-precision diagnostic tools is surging.

Market Overview & Size

The global gastric cancer diagnostics market is characterized by rapid technological integration and expanding clinical accessibility. Based on current industry analysis, the market is expected to reach a valuation of $2.08 billion by 2032.

The forecast year 2026 represents a critical window where AI-enhanced endoscopy and liquid biopsy technologies are moving from clinical trials to standard-of-care. The market is projected to grow at a Compound Annual Growth Rate (CAGR) of 10.90% from 2025 to 2032.

This steady growth is underpinned by the rising incidence of H. pylori infections—a primary risk factor—and an aging global population more susceptible to gastric mutations.

Get a Sample Report of Gastric Cancer Diagnostics Market Forecast @ https://www.databridgemarketresearch.com/nucleus/request-a-sample/global-gastric-cancer-diagnostics-market

Market Segmentation

To address the complexity of stomach cancer, the market is segmented by technology, test type, and end-user:

By Test Type:

Endoscopy: The "gold standard" for visualization and tissue collection.

Imaging: Including CT scans, MRI, and PET scans for staging and metastasis tracking.

Biopsy & Cytology: Definitive laboratory analysis of cellular abnormalities.

By Technology:

Molecular Diagnostics: Using PCR and NGS to identify genetic predispositions.

Immunoassays: Detecting specific tumor markers in the blood or tissue.

AI-Assisted Imaging: Real-time software that helps endoscopists identify subtle mucosal changes.

By End-User:

Hospitals (Leading Share due to surgical and advanced imaging capabilities)

Diagnostic Laboratories

Specialty Clinics

Market Share & Regional Insights

Asia-Pacific holds the largest market share (estimated at over 45%), largely due to the high prevalence of gastric cancer in East Asian countries like Japan, South Korea, and China. These nations have pioneered nationwide screening programs, significantly boosting the demand for diagnostic instruments.

North America and Europe follow, with growth driven by the adoption of expensive molecular testing and a shift toward personalized medicine.

Key Players

The competitive landscape is dominated by diagnostic giants and specialized oncology firms:

Hoffmann-La Roche Ltd.

Abbott Laboratories

Thermo Fisher Scientific Inc.

Agilent Technologies, Inc.

Bio-Rad Laboratories, Inc.

GE Healthcare

Olympus Corporation (Leading the endoscopy segment)

Fujifilm Holdings Corporation

LSI Keyword: Companion Diagnostics

A major trend in 2026 is the rise of companion diagnostics. These are specialized tests developed alongside targeted therapies (such as HER2 inhibitors) to determine if a specific drug will be effective for a patient. By identifying the unique molecular profile of a gastric tumor, companion diagnostics ensure that patients receive the most effective treatment immediately, reducing trial-and-error in oncology.

Frequently Asked Questions (FAQ)

Why is the market projected to grow at 10.90%?This growth is fueled by the integration of Artificial Intelligence (AI) in endoscopy, which increases detection rates of early-stage lesions that were previously missed by the human eye.

Is there a non-invasive alternative to endoscopy?While endoscopy is the most accurate, the market is seeing a rise in "Liquid Biopsies" (blood tests) and breath tests that look for volatile organic compounds associated with gastric cancer. These are primarily used for high-level screening before invasive procedures.

Which region is the fastest-growing for these devices?Asia-Pacific remains the fastest-growing region due to high disease burden and increasing healthcare expenditure in emerging economies.

Future outlook

By 2032, the Gastric Cancer Diagnostics Market will have matured into a $2.08 billion industry, defined by the marriage of imaging and molecular science. The year 2026 stands as a gateway for the mass adoption of AI and companion diagnostics, which will collectively lower mortality rates through earlier, more precise detection. For providers, the shift toward minimally invasive, high-accuracy testing is no longer just a trend—it is a clinical necessity.

About Us:

Data Bridge Is One Of The Leading Market Research And Consulting Agencies That Dominates The Market Research Industry Globally. Our Company's Aim Is To Give Clients The Knowledge They Require In Order To Function In Changing Circumstances. In Order To Give You Current, Accurate Market Data, Consumer Insights, And Opinions So That You Can Make Decisions With Confidence, We Employ a Variety Of Techniques, Including Surveys, Video Talks, And Focus Groups Around The World.

Leading Market Players With Their Product Listed In This Report Are:

For More Region Related Reports:

Contact :

Data Bridge Market Research Private Ltd .

3665 Kingsway - Suite 300 Vancouver Bc V5R 5W2 Canada

+1 614 591 3140 (Us)

+44 845 154 9652 (Uk)